|Biotech Due Diligence||
A new round-up of new items and previous links that I had managed to miss. Maybe you did too? Sorry for the lack of biotech reading list editions lately - good thing we all have the Endpoints newsletter to fill in the gap.
Catch up on the top stories from the world of medical devices, curated by Chris Ware (@ware_am_i):
Medtronic (MDT) Receives FDA Clearance for Expanded NuVent Indication
Street Insider ($MDT)
St. Jude Medical Continues To Expand Its Heart Failure Portfolio In The U.S. To Provide Physicians Additional Options For Managing Patients Not Responding To Other Therapies
Press Release ($STJ)
MedTech Industry Stock Outlook - July 2016
Zacks ($MDT) ($JNJ) ($EW)
How Will Abbott Labs (ABT) Stock Be Impacted by FTC Requests?
Rachel Aldrich, The Street ($ABT) ($STJ)
3 Key Things I’ll Be Looking for When Intuitive Surgical, Inc. Reports Next Week
Brian Stoffel, Motley Fool ($ISRG)
Zimmer Biomet Completes Tender Offer For Outstanding Shares Of LDR Holding Corporation
Press Release ($ZBT)
Medtronic's IN.PACT Admiral DCB Wins FDA Nod for 150 mm
Once again, we take to the Twitterverse for a collection of new scientific and medical journal articles that are driving the biotech conversation.
A new week means a new edition of the Medical Device Reading List from Chris Ware @ware_am_i).
Medtronic Acquires HeartWare With Some Activist Inspiration
David Marcus, The Street ($MDT)
Fears Over Cardinal Health Are Overblown
Jonathan Wheeler, Seeking Alpha ($CAH)
NuVasive (NUVA), Medtronic (MDT) Agree to Settle Patent Litigation
StreetInsider ($MDT, $NUVA)
Medtronic Aims to Build $40 Billion in Free Cash Flow: Here’s How
Sarah Collins, Market Realist ($MDT)
About Abbott Labs' Acquisition Of St. Jude Medical
Casey Hoerth, Seeking Alpha ($ABT, $STJ)
Medtronic Launches Heart Failure Management Service, Files PMA For "Artificial Pancreas"
Jof Enriquez, Med Device Online ($MDT)
What a busy week as the second quarter came to a close with a flurry of data announcements. Catch up on all the action with the latest edition of the Biotech Tweets of the Week, curated by @23aloha and @BioDueDiligence. This installment features:
-GW Pharma delivers another win with cannabis drug $GWPH
-Regulus falls farther behind the HCV field with clinical hold $RGLS
-F is for fail... Bad data from $CYAD $AMPE $MRNS $GALE
-Another bump in the road for Esperion's cholesterol drug $ESPR
-Tesaro's ovarian cancer data spurs PARP resurgence $TSRO
-On the topic of debt $ICPT et al
-As seen on the stream (the best of everything else)
Your support is greatly appreciated